If Eli Lilly's obesity pill orforglipron is approved and priced around $200 per month, analysts at Truist predict patients ...

Within five business days, Alkermes can negotiate with Avadel to amend its original takeover offer to beat Lundbeck.

Winrevair yielded significant and meaningful clinical benefits for patients with combined post- and precapillary pulmonary ...

Communication must be viewed as more than the last step of the research process. It is the structure that makes scientific ...

The FDA approval of the siRNA drug Redemplo caps off a tumultuous 12 months for Arrowhead, whose partnership with Sarepta ...

A spokesperson for the FDA said the agency is “considering a wide range of options to support American innovation." ...

In May, a BioSpace survey found that 56% of employed biopharma professionals are considering jobs outside the industry. Among the unemployed, that number jumps to 81%. In another pulse check, an ...

Novo Nordisk goes "on the offensive" following Trump deal that also included rival Eli Lilly, putting an exclamation point on rapidly declining GLP-1 drug prices. Experts say the unusual situation ...

Only one clinical-stage asset from the ProfoundBio acquisition remains in development: The antibody-drug conjugate Rina-S, in ...

Nxera, which formerly went by Sosei, will also reprioritize its pipeline to focus on obesity, metabolic and endocrine ...

The industry’s ability to generate a return on billions of dollars of investment rests on a heavily regulated supply chain ...

Halda Therapeutics is developing oral assets for prostate and lung cancer. The deal comes after Johnson & Johnson set an ...